Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chroni...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

NasdaqFrontier Jun. 30 at 1:45 PM

$JSPR price check at 0.40. The company is navigating a critical phase following the announcement of a strategic alternatives review. With significant capital constraints and no revenue stream, the outlook remains highly uncertain. Market participants should be wary of further downside volatility.

0 · Reply

Gadotti777 Jun. 30 at 12:18 PM

$JSPR @FIREINSP Your comment would be entirely correct if the individuals on this company's board weren't so highly respected in the market and didn't possess such extensive track records of major deals. If you look into it, this company has invested far more in top-tier talent than others in the sector—and, it must be said, these are heavyweights in the market. That is why I have great confidence in this case.

1 · Reply

FIREINSP Jun. 29 at 9:37 PM

$JSPR This smells of a rug pull…

0 · Reply

topstockalerts Jun. 29 at 9:25 PM

$JSPR this has that “don’t overthink it” look.

0 · Reply

Hotrod49 Jun. 29 at 8:00 PM

$JSPR $5.00

1 · Reply

Hotrod49 Jun. 29 at 8:00 PM

$JSPR nice and easy baby

0 · Reply

Hotrod49 Jun. 29 at 7:59 PM

$JSPR

0 · Reply

like11 Jun. 29 at 7:57 PM

$JSPR

0 · Reply

Gadotti777 Jun. 29 at 1:39 PM

$JSPR With the individuals serving as CEO, CFO, and directors, this company has tremendous potential to be sold or traded at a value far exceeding its current trading price. We can expect great news regarding JSPR soon.

0 · Reply

shehww Jun. 26 at 9:34 PM

$JSPR wtf 🫣...

0 · Reply

Jasper Therapeutics Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 19 days ago

Jasper Therapeutics Proxy statement: Proxy filing

2026-06-01T12:26:26.000Z - 4 weeks ago

Jasper Therapeutics initiates review of strategic alternatives

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

2026-05-15T13:18:13.000Z - 7 weeks ago

Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital

2026-05-15T09:40:09.000Z - 7 weeks ago

Jasper Therapeutics downgraded to Hold from Buy at TD Cowen

May 14, 2026, 4:05 PM EDT - 7 weeks ago

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Jasper Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Jasper Therapeutics Earnings release: Q1 2026

2026-04-01T11:59:40.000Z - 3 months ago

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI

2026-03-30T20:37:13.000Z - 3 months ago

Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)

Mar 30, 2026, 4:30 PM EDT - 3 months ago

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Jasper Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Jasper Therapeutics Annual report: Q4 2025

2026-03-23T10:20:58.000Z - 3 months ago

Jasper Therapeutics assumed with a Neutral at UBS

Mar 2, 2026, 3:50 PM EST - 4 months ago

Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:00 AM EST - 4 months ago

Jasper Therapeutics Slides: Corporate presentation

Feb 24, 2026, 4:30 PM EST - 4 months ago

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

2026-01-13T20:20:15.000Z - 6 months ago

Jasper Therapeutics initiated with a Buy at Rodman & Renshaw

Jan 8, 2026, 8:00 AM EST - 6 months ago

Jasper Therapeutics Transcript: Study Result

Jan 8, 2026, 8:00 AM EST - 6 months ago

Jasper Therapeutics Press release: Study Result

Jan 8, 2026, 8:00 AM EST - 6 months ago

Jasper Therapeutics Slides: Study Result

2026-01-08T12:15:17.000Z - 6 months ago

Jasper Therapeutics reports updated data from briquilimab studies

Jan 8, 2026, 7:00 AM EST - 6 months ago

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

2026-01-07T21:35:34.000Z - 6 months ago

Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO

Jan 7, 2026, 4:30 PM EST - 6 months ago

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

2025-12-04T16:57:00.000Z - 7 months ago

3 Penny Stocks to Watch Now, 12/4/25

Dec 3, 2025, 3:00 PM EST - 7 months ago

Jasper Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:00 AM EST - 7 months ago

Jasper Therapeutics Transcript: Study Result

Dec 2, 2025, 8:00 AM EST - 7 months ago

Jasper Therapeutics Press release: Study Result

Dec 2, 2025, 8:00 AM EST - 7 months ago

Jasper Therapeutics Slides: Study Result

2025-12-02T12:10:33.000Z - 7 months ago

Jasper Therapeutics reports data from ETESIAN Phase 1b study

Dec 2, 2025, 7:00 AM EST - 7 months ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 1, 2025, 4:30 PM EST - 7 months ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Nov 12, 2025, 3:30 PM EST - 8 months ago

Jasper Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 11, 2025, 4:00 PM EST - 8 months ago

Jasper Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 7:00 AM EST - 8 months ago

Jasper Therapeutics Slides: Investor Presentation

2025-11-10T13:05:12.000Z - 8 months ago

Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)

Nov 10, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Earnings release: Q3 2025

Nov 9, 2025, 6:00 PM EST - 8 months ago

Jasper Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Sep 22, 2025, 1:05 PM EDT - 10 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

2025-09-22T10:55:06.000Z - 10 months ago

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

2025-09-19T10:00:28.000Z - 10 months ago

Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43

Sep 19, 2025, 12:07 AM EDT - 10 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

2025-09-18T20:15:24.000Z - 10 months ago

Jasper Therapeutics announces common stock offering, no amount given

Sep 18, 2025, 4:08 PM EDT - 10 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 3, 2025, 1:00 PM EDT - 10 months ago

Jasper Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 6:00 PM EDT - 10 months ago

Jasper Therapeutics Slides: Corporate Presentation

2025-08-15T11:35:55.000Z - 11 months ago

Jasper Therapeutics price target lowered to $25 from $29 at UBS

2025-08-13T20:35:13.000Z - 11 months ago

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)

Aug 13, 2025, 4:05 PM EDT - 11 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 7:00 AM EDT - 11 months ago

Jasper Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 11 months ago

Jasper Therapeutics Quarterly report: Q2 2025

2025-07-09T12:15:18.000Z - 1 year ago

Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

2025-07-08T10:25:33.000Z - 1 year ago

RBC downgrades Jasper Therapeutics on questions about briquilimab

CLDX

2025-07-08T09:45:23.000Z - 1 year ago

Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Study Update

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Press release: Study Update

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Slides: Study Update

Jul 7, 2025, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Slides: Investor Presentation

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Press release: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Status Update

Jun 14, 2025, 10:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 21, 2025, 11:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 4:05 PM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Quarterly report: Q1 2025

Mar 27, 2025, 12:30 PM EDT - 1 year ago

Jasper Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Registration statement: Registration Filing

Mar 3, 2025, 1:20 PM EST - 1 year ago

Jasper Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 1, 2025, 12:45 PM EST - 1 year ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Earnings release: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Transcript: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Press release: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Slides: Study Update

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 3, 2024, 3:25 PM EST - 1 year ago

Jasper Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 9:45 AM EST - 1 year ago

Jasper Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Quarterly report: Q3 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Press release: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Study Result

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 20, 2024, 12:00 PM EDT - 1 year ago

Jasper Therapeutics Transcript: TD Cowen Chronic Urticaria Summit

Sep 17, 2024, 2:30 PM EDT - 1 year ago

Jasper Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 3:00 PM EDT - 1 year ago

Jasper Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 10, 2024, 6:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Corporate Presentation

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

NasdaqFrontier Jun. 30 at 1:45 PM

0 · Reply

Gadotti777 Jun. 30 at 12:18 PM

1 · Reply

FIREINSP Jun. 29 at 9:37 PM

$JSPR This smells of a rug pull…

0 · Reply

topstockalerts Jun. 29 at 9:25 PM

$JSPR this has that “don’t overthink it” look.

0 · Reply

Hotrod49 Jun. 29 at 8:00 PM

$JSPR $5.00

1 · Reply

Hotrod49 Jun. 29 at 8:00 PM

$JSPR nice and easy baby

0 · Reply

Hotrod49 Jun. 29 at 7:59 PM

$JSPR

0 · Reply

like11 Jun. 29 at 7:57 PM

$JSPR

0 · Reply

Gadotti777 Jun. 29 at 1:39 PM

0 · Reply

shehww Jun. 26 at 9:34 PM

$JSPR wtf 🫣...

0 · Reply

Reesifer Jun. 26 at 7:56 PM

$JSPR added .345

0 · Reply

Biotech41 Jun. 26 at 6:59 PM

$JSPR what a gap : 52W High $7.19 52W Low $0.42

1 · Reply

Biotech41 Jun. 26 at 6:59 PM

$JSPR no news...

0 · Reply

Mario19860 Jun. 26 at 5:17 PM

$JSPR is this end?

1 · Reply

Mario19860 Jun. 24 at 2:55 PM

$JSPR something new?

0 · Reply

Mario19860 Jun. 16 at 1:44 PM

$JSPR what happening?

1 · Reply

Zackpedia Jun. 9 at 11:46 PM

$JSPR Down to .42 today, you could’ve sold as I alerted

0 · Reply

Assel17 Jun. 8 at 8:06 AM

$JSPR There is no major positive news at the moment. The stock is still in a "waiting for the big news" phase, and any announcement of: An acquisition offer, A merger, A partnership with a major pharmaceutical company, Or a drug licensing agreement, could have a significant impact on the share price.

1 · Reply

ShadowNick Jun. 7 at 11:03 PM

$JSPR target for this month 1$+ pls

1 · Reply

Assel17 Jun. 4 at 7:36 PM

$JSPR all in

0 · Reply

MaxPain_Trader Jun. 4 at 5:57 PM

$JSPR thanks sellers and shorters for the dip. Helps with the upcoming MOASS

0 · Reply

shehww Jun. 3 at 2:24 PM

$JSPR

0 · Reply

Market Cap	11.99M
Revenue (ttm)	0.00
Net Income (ttm)	-75.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	221,900
Avg Vol	485,738
Day's Range	N/A - N/A
Shares Out	28.00M
Stochastic %K	40%
Beta	3.07
Analysts	Sell
Price Target	$7.50